Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Funding Is Secured At Visterra, Pearl
by Lisa M. Jarvis
November 19, 2012
| A version of this story appeared in
Volume 90, Issue 47
Visterra has completed a $26 million Series A financing round. The Bill & Melinda Gates Foundation and Omega Funds joined three existing investors in the effort. Cambridge, Mass.-based Visterra will use the funds to develop its pipeline of antibodies to treat infectious diseases. Separately, Pearl Therapeutics has secured $65 million in its latest financing round, which involved existing investors. The Redwood City, Calif.-based firm will use the cash to initiate a Phase III study of PT003, a treatment for chronic obstructive pulmonary disease.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X